-
Something wrong with this record ?
Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)
L. Součková, R. Opatřilová, P. Suk, I. Čundrle, M. Pavlík, V. Zvoníček, O. Hlinomaz, V. Šrámek,
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
CINAHL Plus with Full Text (EBSCOhost)
from 2008-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Purinergic P2 Receptor Antagonists administration & dosage blood pharmacokinetics MeSH
- Administration, Oral MeSH
- Biological Availability MeSH
- Intubation, Gastrointestinal MeSH
- Platelet Aggregation Inhibitors administration & dosage blood pharmacokinetics MeSH
- Cardiopulmonary Resuscitation * MeSH
- Percutaneous Coronary Intervention * instrumentation MeSH
- Critical Illness MeSH
- Middle Aged MeSH
- Humans MeSH
- Receptors, Purinergic P2 drug effects metabolism MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Stents MeSH
- Tablets MeSH
- Hypothermia, Induced MeSH
- Ticlopidine administration & dosage analogs & derivatives blood pharmacokinetics MeSH
- Blood Platelets drug effects metabolism MeSH
- Thrombelastography MeSH
- Respiration, Artificial MeSH
- Chromatography, High Pressure Liquid MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
PURPOSE: Bioavailability of clopidogrel in the form of crushed tablets administered via nasogastric tube (NGT) has not been established in patients after cardiopulmonary resuscitation. Therefore, we performed a study comparing pharmacokinetic and pharmacodynamic response to high loading dose of clopidogrel in critically ill patients after cardiopulmonary resuscitation (CPR) with patients scheduled for elective coronary angiography with stent implantation. METHODS: In the NGT group (nine patients, after cardiopulmonary resuscitation, mechanically ventilated, therapeutic hypothermia), clopidogrel was administered in the form of crushed tablets via NGT. Ten patients undergoing elective coronary artery stenting took clopidogrel per os (po) in the form of intact tablets. Pharmacokinetics of clopidogrel was measured with high-performance liquid chromatography (HPLC) before and at 0.5, 1, 6, 12, 24 h after administration of a loading dose of 600 mg. In five patients in each group, antiplatelet effect was measured with thrombelastography (TEG; Platelet Mapping) before and 24 h after administration. RESULTS: The carboxylic acid metabolite of clopidogrel was detected in all patients in the po group. In eight patients, the maximum concentration was measured in the range of 0.5-1 h after the initial dose. In four patients in the of NGT group, the carboxylic acid metabolite of clopidogrel was undetectable and in the remaining patients was significantly delayed (peak values at 12 h). All patients in the po group reached clinically relevant (>50 %) inhibition of thrombocyte adenosine diphosphate (ADP) receptor after 24 h compared with only two in the NGT group (p = 0.012). There was a close correlation between peak of inactive clopidogrel metabolite plasmatic concentration and inhibition of the ADP receptor (r = 0.79; p < 0.001). CONCLUSION: The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients. Therefore, other drugs, preferentially administered intravenously, should be considered.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031890
- 003
- CZ-PrNML
- 005
- 20131004113019.0
- 007
- ta
- 008
- 131002s2013 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00228-012-1360-0 $2 doi
- 035 __
- $a (PubMed)22890586
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Součková, L $u Department of Anaesthesiology and Intensive Care, University Hospital St. Anne's Brno, Brno, Czech Republic.
- 245 10
- $a Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR) / $c L. Součková, R. Opatřilová, P. Suk, I. Čundrle, M. Pavlík, V. Zvoníček, O. Hlinomaz, V. Šrámek,
- 520 9_
- $a PURPOSE: Bioavailability of clopidogrel in the form of crushed tablets administered via nasogastric tube (NGT) has not been established in patients after cardiopulmonary resuscitation. Therefore, we performed a study comparing pharmacokinetic and pharmacodynamic response to high loading dose of clopidogrel in critically ill patients after cardiopulmonary resuscitation (CPR) with patients scheduled for elective coronary angiography with stent implantation. METHODS: In the NGT group (nine patients, after cardiopulmonary resuscitation, mechanically ventilated, therapeutic hypothermia), clopidogrel was administered in the form of crushed tablets via NGT. Ten patients undergoing elective coronary artery stenting took clopidogrel per os (po) in the form of intact tablets. Pharmacokinetics of clopidogrel was measured with high-performance liquid chromatography (HPLC) before and at 0.5, 1, 6, 12, 24 h after administration of a loading dose of 600 mg. In five patients in each group, antiplatelet effect was measured with thrombelastography (TEG; Platelet Mapping) before and 24 h after administration. RESULTS: The carboxylic acid metabolite of clopidogrel was detected in all patients in the po group. In eight patients, the maximum concentration was measured in the range of 0.5-1 h after the initial dose. In four patients in the of NGT group, the carboxylic acid metabolite of clopidogrel was undetectable and in the remaining patients was significantly delayed (peak values at 12 h). All patients in the po group reached clinically relevant (>50 %) inhibition of thrombocyte adenosine diphosphate (ADP) receptor after 24 h compared with only two in the NGT group (p = 0.012). There was a close correlation between peak of inactive clopidogrel metabolite plasmatic concentration and inhibition of the ADP receptor (r = 0.79; p < 0.001). CONCLUSION: The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients. Therefore, other drugs, preferentially administered intravenously, should be considered.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a biologická dostupnost $7 D001682
- 650 _2
- $a trombocyty $x účinky léků $x metabolismus $7 D001792
- 650 12
- $a kardiopulmonální resuscitace $7 D016887
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a kritický stav $7 D016638
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a terapeutická hypotermie $7 D007036
- 650 _2
- $a gastrointestinální intubace $7 D007441
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a koronární angioplastika $x přístrojové vybavení $7 D062645
- 650 _2
- $a inhibitory agregace trombocytů $x aplikace a dávkování $x krev $x farmakokinetika $7 D010975
- 650 _2
- $a antagonisté purinergního receptoru P2 $x aplikace a dávkování $x krev $x farmakokinetika $7 D058919
- 650 _2
- $a purinergní receptory P2 $x účinky léků $x metabolismus $7 D018048
- 650 _2
- $a umělé dýchání $7 D012121
- 650 _2
- $a stenty $7 D015607
- 650 _2
- $a tablety $7 D013607
- 650 _2
- $a tromboelastografie $7 D013916
- 650 _2
- $a tiklopidin $x aplikace a dávkování $x analogy a deriváty $x krev $x farmakokinetika $7 D013988
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Opatřilová, R $u -
- 700 1_
- $a Suk, P $u -
- 700 1_
- $a Čundrle, I $u -
- 700 1_
- $a Pavlík, M $u -
- 700 1_
- $a Zvoníček, V $u -
- 700 1_
- $a Hlinomaz, O $u -
- 700 1_
- $a Šrámek, V $u -
- 773 0_
- $w MED00001613 $t European journal of clinical pharmacology $x 1432-1041 $g Roč. 69, č. 3 (2013), s. 309-17
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22890586 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131004113538 $b ABA008
- 999 __
- $a ok $b bmc $g 995977 $s 830335
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 69 $c 3 $d 309-17 $i 1432-1041 $m European journal of clinical pharmacology $n Eur J Clin Pharmacol $x MED00001613
- LZP __
- $a Pubmed-20131002